Skip to content
Clinical Trials – home
Therapeutic area

Vascular disorders – page 21

  • 838 clinical trials
  • 353 recruiting
  • 378 conditions
  • 28 countries

Conditions in this area

378 conditions with trials, the busiest first

Clinical trials in Vascular disorders

838 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

838 clinical trials

Study on Apathy in Stroke Patients Using Fluoroethoxybenzovesamicol F-18 and Fluorodopa (18F)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorodopa (18F)
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Study of [18F]AlF-NOTA-Octreotide for Carotid Artery Disease in Patients with Recent Stroke or TIA

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[18F]Alf-Nota-Octreotide
  • Sponsor:UZ Leuven

Comparison of Once Versus Twice Daily Prednisolone Administration on Blood Glucose Control in Patients with ANCA-Associated Vasculitis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Medical University Of Graz

Study on the Safety and Benefits of Recombinant Human Plasma Gelsolin for Patients with Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Plasma Gelsolin, Recombinant
  • Sponsor:Bioaegis Therapeutics Inc.

Study on Tenecteplase and Alteplase for Patients with Acute Ischemic Stroke Due to Basilar Artery Blockage

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Alteplase
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Study Comparing Two Prednisone Treatment Plans for Patients with Giant Cell Arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Study on the Effects of Continuing or Stopping Simvastatin and Atorvastatin in Patients with Spontaneous Lobar Intracerebral Hemorrhage

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Atorvastatin
  • Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau

Study of Belimumab versus Placebo for Treatment of Non-infectious Active Cryoglobulinemia Vasculitis in Adult Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Psilocybin and Midazolam for Reducing Atherosclerosis in Patients with Coronary Artery Disease

InvestigationalNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Midazolam
  • Sponsor:Psyon s.r.o.

Study on the Safety of Allogeneic Adipose-Derived Mesenchymal Stromal Cells for Patients with Severe Systemic Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic Adipose-Derived Mesenchymal Stromal Cells, Ex-Vivo Expanded
  • Sponsor:Assistance Publique Hopitaux De Paris

Study on Apixaban and Edoxaban for Preventing Stroke in Patients with Recent Perioperative Atrial Fibrillation After Noncardiac Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Hamilton Health Sciences Corporation

Study on Bevacizumab for Patients with Symptomatic Cerebral Arteriovenous Malformations

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondation A De Rothschild

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.